Ixazomib

What it is used for

NINLARO ® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Side effects, and when to stop

The following adverse reactions are described in detail in other sections of the prescribing information:

• Thrombocytopenia
• Gastrointestinal Toxicities
• Peripheral Neuropathy
• Peripheral Edema
• Cutaneous Reactions
• Thrombotic Microangiopathy
• Hepatotoxicity

Who should not take it

None.

Storing it

Storage

Store NINLARO at room temperature. Do not store above 30°C (86°F). Do not freeze.

Store capsules in original packaging until immediately prior to use.

Handling and Disposal

NINLARO is a hazardous drug. Follow applicable special handling and disposal procedures 1.

Do not open or crush capsules. Avoid direct contact with the capsule contents. In case of capsule breakage, avoid direct contact of capsule contents with the skin or eyes. If contact occurs with the skin, wash thoroughly with soap and water. If contact occurs with the eyes, flush thoroughly with water.

Any unused medicinal product or waste material should be disposed in accordance with local requirements.